The core limitation is the low natural yield and slow synthesis rates of purine nucleotides in wild-type microorganisms. Increasing metabolic throughput is necessary to achieve commercially viable production levels.

The cluster focuses on the inherent limitations of wild-type microorganisms to produce purine nucleotides at industrial scales. Overcoming metabolic bottlenecks and feedback inhibition allows for commercially viable production rates.

Natural microbial pathways lack the throughput required for industrial-scale purine synthesis. Increasing metabolic flux overcomes rate-limiting steps to enable commercially viable production yields.